Cargando…
Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with almost 3000 different disease-causing variants within the NF1 gene identified. Up to 44% of these variants cause splicing errors to occur within pre-mRNA. A recurrent variant in exon 13, c.1466A>G; p.Y489C (Y489C) resul...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705852/ https://www.ncbi.nlm.nih.gov/pubmed/34945792 http://dx.doi.org/10.3390/jpm11121320 |
_version_ | 1784622049202798592 |
---|---|
author | Awad, Elias K. Moore, Marc Liu, Hui Ciszewski, Lukasz Lambert, Laura Korf, Bruce R. Popplewell, Linda Kesterson, Robert A. Wallis, Deeann |
author_facet | Awad, Elias K. Moore, Marc Liu, Hui Ciszewski, Lukasz Lambert, Laura Korf, Bruce R. Popplewell, Linda Kesterson, Robert A. Wallis, Deeann |
author_sort | Awad, Elias K. |
collection | PubMed |
description | Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with almost 3000 different disease-causing variants within the NF1 gene identified. Up to 44% of these variants cause splicing errors to occur within pre-mRNA. A recurrent variant in exon 13, c.1466A>G; p.Y489C (Y489C) results in the creation of an intragenic cryptic splice site, aberrant splicing, a 62 base pair deletion from the mRNA, and subsequent frameshift. We investigated the ability of phosphorodiamidate morpholino oligomers (PMOs) to mask this variant on the RNA level, thus restoring normal splicing. To model this variant, we have developed a human iPS cell line homozygous for the variant using CRISPR/Cas9. PMOs were designed to be 25 base pairs long, and to cover the mutation site so it could not be read by splicing machinery. Results from our in vitro testing showed restoration of normal splicing in the RNA and restoration of full length neurofibromin protein. In addition, we observe the restoration of neurofibromin functionality through GTP-Ras and pERK/ERK testing. The results from this study demonstrate the ability of a PMO to correct splicing errors in NF1 variants at the RNA level, which could open the door for splicing corrections for other variants in this and a variety of diseases. |
format | Online Article Text |
id | pubmed-8705852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87058522021-12-25 Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C Awad, Elias K. Moore, Marc Liu, Hui Ciszewski, Lukasz Lambert, Laura Korf, Bruce R. Popplewell, Linda Kesterson, Robert A. Wallis, Deeann J Pers Med Article Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with almost 3000 different disease-causing variants within the NF1 gene identified. Up to 44% of these variants cause splicing errors to occur within pre-mRNA. A recurrent variant in exon 13, c.1466A>G; p.Y489C (Y489C) results in the creation of an intragenic cryptic splice site, aberrant splicing, a 62 base pair deletion from the mRNA, and subsequent frameshift. We investigated the ability of phosphorodiamidate morpholino oligomers (PMOs) to mask this variant on the RNA level, thus restoring normal splicing. To model this variant, we have developed a human iPS cell line homozygous for the variant using CRISPR/Cas9. PMOs were designed to be 25 base pairs long, and to cover the mutation site so it could not be read by splicing machinery. Results from our in vitro testing showed restoration of normal splicing in the RNA and restoration of full length neurofibromin protein. In addition, we observe the restoration of neurofibromin functionality through GTP-Ras and pERK/ERK testing. The results from this study demonstrate the ability of a PMO to correct splicing errors in NF1 variants at the RNA level, which could open the door for splicing corrections for other variants in this and a variety of diseases. MDPI 2021-12-07 /pmc/articles/PMC8705852/ /pubmed/34945792 http://dx.doi.org/10.3390/jpm11121320 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Awad, Elias K. Moore, Marc Liu, Hui Ciszewski, Lukasz Lambert, Laura Korf, Bruce R. Popplewell, Linda Kesterson, Robert A. Wallis, Deeann Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C |
title | Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C |
title_full | Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C |
title_fullStr | Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C |
title_full_unstemmed | Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C |
title_short | Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C |
title_sort | restoration of normal nf1 function with antisense morpholino treatment of recurrent pathogenic patient-specific variant c.1466a>g; p.y489c |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705852/ https://www.ncbi.nlm.nih.gov/pubmed/34945792 http://dx.doi.org/10.3390/jpm11121320 |
work_keys_str_mv | AT awadeliask restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT mooremarc restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT liuhui restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT ciszewskilukasz restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT lambertlaura restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT korfbrucer restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT popplewelllinda restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT kestersonroberta restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c AT wallisdeeann restorationofnormalnf1functionwithantisensemorpholinotreatmentofrecurrentpathogenicpatientspecificvariantc1466agpy489c |